Anti-Fibrotic
Anti-fibrotic research targets the pathological deposition of extracellular matrix in chronic tissue injury (cardiac, pulmonary, renal, hepatic fibrosis). Thymosin Beta-4 (and its TB-500 fragment) has documented anti-fibrotic activity in cardiac and dermal models. The Ac-SDKP fragment of Thymosin Beta-4 is the specifically anti-fibrotic active site.
